Bateman, A. C. and E. C. Shaw (2013). "Breast pathology." Surgery (Oxford) 31(1): 4-10.
Dole, M. G., R. Jasty, M. J. Cooper, C. B. Thompson, G. Nuñez and V. P. Castle (1995). "Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis." Cancer research 55(12): 2576-2582.
Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin (2010). "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008." International journal of cancer 127(12): 2893-2917.
Lacroix, M. and G. Leclercq (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update." Breast cancer research and treatment 83(3): 249-289.
Leung, L. K. and T. T. Wang (1999). "Differential effects of chemotherapeutic agents on the Bcl‐2/Bax apoptosis pathway in human breast cancer cell line MCF‐7." Breast cancer research and treatment 55(1): 73-83.
Lippman, M. E. and R. B. DICKSON'r (2013). Mechanisms of growth control in normal and malignant breast epithelium. Recent Progress in Hormone Research: Proceedings of the 1988 Laurentian Hormone Conference, Academic Press.
Lüpertz, R., W. Wätjen, R. Kahl and Y. Chovolou (2010). "Dose-and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells." Toxicology 271(3): 115-121.
Mcgahon, A. J., A. P. Costa Pereira, L. Daly and T. G. Cotter (1998). "Chemotherapeutic drug‐induced apoptosis in human leukaemic cells is independent of the Fas (APO‐1/CD95) receptor/ligand system." British journal of haematology 101(3): 539-547
.
Minn, A. J., C. M. Rudin, L. H. Boise and C. B. Thompson (1995). "Expression of bcl-xL can confer a multidrug resistance phenotype." Blood 86(5): 1903-1910.
Nazário, A. C. P., G. Facina and J. R. Filassi (2015). "Breast cancer: news in diagnosis and treatment." Revista da Associação Médica Brasileira 61(6): 543-552.
Pritchard, J. E., P. M. Dillon, M. R. Conaway, C. M. Silva and S. J. Parsons (2012). "A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model." Oncology 83(6): 305-320.
Puhalla, S., S. Bhattacharya and N. E. Davidson (2012). "Hormonal therapy in breast cancer: a model disease for the personalization of cancer care." Molecular oncology 6(2): 222-236.
Rusetskaya, N., N. Y. Lukyanova and V. Chekhun (2009). "Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin." Exp Oncol 31: 140-143.
Sharifi, S., J. Barar, M. S. Hejazi and N. Samadi (2015). "Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells." Advanced pharmaceutical bulletin 5(3): 351.
Sharma, G., A. K. Tyagi, R. P. Singh, D. C. Chan and R. Agarwal (2004). "Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells." Breast cancer research and treatment 85(1): 1-12.
Sotiriou, C., S.-Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. B. Fox, A. L. Harris and E. T. Liu (2003). "Breast cancer classification and prognosis based on gene expression profiles from a population-based study." Proceedings of the National Academy of Sciences 100(18): 10393-10398.
Teixeira, C., J. C. Reed and M. C. Pratt (1995). "Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells." Cancer research 55(17): 3902-3907.